Article
Biosimilar Basics for Oncology Nurses and Patients
“The way I approach patient education conversations is to discuss it, address it, but not to emphasize it. I really like to focus on what the drug is. I mention if it’s a biosimilar, I explain it, I give resources if they want it, but I really try to focus on the things that they’re going to need to know in order to help be part of their care, but have readily available information to give them if they want more,” ONS affiliate member Rowena (Moe) Schwartz, PharmD, BCOP, professor of pharmacy practice at the University of Cincinnati in Ohio, told Jaime Weimer, MSN, RN, AGCNS-BC, AOCNS®, oncology clinical specialist at ONS during a discussion about the basics of biosimilars for nurses and patients.
Related Topics
You May Also Like
Article
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
Article
Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review
Article
Transforming oncology: Five frontiers driving progress in cancer care
Article
Virtual Oncology MSL Team Increases KOL Engagement by 120%
Article